FDA warned Ikcon Medical that it sold unapproved COVID-19 antibody and antigen tests online and made misleading 'FDA registered' claims.
What happened
FDA reviewed www.ikconmedical.com and www.akcutestshop.com on February 3, 4, and 11, 2021. FDA found that www.akcutestshop.com offered the Akcutest COVID-19 Antibody Test and Lumigenik COVID-19 Antigen Rapid Test for sale in the United States without FDA marketing approval, clearance, or authorization; FDA called the products adulterated (not legally approved) and misbranded (mislabeled or misleading). FDA also found 'FDA registered' statements and unauthorized FDA logo use near Akcutest information, and its database showed no Ikcon establishment registration and no Akcutest device listing.
What FDA found
The company offered two COVID-19 tests for sale in the U.S. without FDA approval, clearance, or authorization.
section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B)The company did not notify FDA before introducing the tests into commercial distribution, as required by the 510(k) premarket notification process (FDA's premarket review request).
section 502(o) of the Act, 21 U.S.C. § 352(o); section 510(k) of the Act, 21 U.S.C. § 360(k)The company's actions with the devices after interstate shipment resulted in the devices being misbranded.
section 301(k) of the Act, 21 U.S.C. § 331(k)The Akcutest Kit labeling was false or misleading because 'FDA registered' and FDA logo references implied FDA approval, clearance, or authorization that did not exist; a small disclaimer did not fix the impression.
section 502(a) of the Act, 21 U.S.C. § 352(a); 21 CFR 807.39FDA's database showed no establishment named Ikcon was registered and no device named Akcutest was listed, so the 'FDA registered' statements also appeared false.
21 CFR 807.39Shipping these products between states is prohibited.
section 301(a) of the Act, 21 U.S.C. § 331(a)
What FDA wants
FDA tells the company to take immediate action to stop selling the unapproved, uncleared, and unauthorized COVID-19 products and to review its websites, labels, and promotional materials. The company must email FDA within 48 hours describing the steps taken and how it will prevent recurrence, or explain why it cannot complete the actions within 48 hours and give a timeline.
Who should pay attention
- online sellers of COVID-19 test kits
- companies using 'FDA registered' or FDA logo in device marketing
- buyers of antibody or antigen tests from small distributors
This is a summary. Read the original letter on fda.gov.